Results 51 to 60 of about 348 (143)
Concentrations of H1‐Receptor Antagonist in the Human Nasal Mucosa
Aims. To measure blood and tissue concentrations of the H1‐receptor antagonist, bepotastine besilate (BB). Methods. Participants included 14 men and six women, whose age ranged from 13 to 76 years, with chronic rhinosinusitis, who underwent endoscopic sinus surgery at our university hospital.
Kenji Takasaki +4 more
wiley +1 more source
Double‐Blind Placebo‐Controlled Trial of Bepotastine Salicylate in Patients With Allergic Rhinitis
Objectives/HypothesisTo evaluate the efficacy and safety of a slow‐release form of bepotastine salicylate (HL151, Belion CR) in patients with perennial allergic rhinitis (PAR).Study DesignDouble‐blind, placebo‐controlled multicenter comparative study.MethodsTwo hundred seventy‐two PAR patients (aged 19–65 years) were studied to determine the efficacy ...
Ji‐Hun Mo +12 more
openaire +3 more sources
Craig F McCabe, Shannon E McCabeMcCabe Vision Center, Murfreesboro, TN, USABackground: The aim of this study was to compare patient-perceived relief of ocular itch, nasal symptoms, and eye drop comfort when allergic conjunctivitis was treated with ...
McCabe CF, McCabe SE
doaj
Immediate Clinical Effectiveness of Bepotastine Besilate for Patients with Urticaria
蕁麻疹患者25例を対象として,ベシル酸ベポタスチン錠(タリオン®錠)の即効性と有用性に関するアンケート調査を行なった。即効性(内服後痒みの抑制効果を自覚した時間)に関しては回答を得た20例で,全例が内服後90分以内に痒みの抑制効果を自覚していた(内服後30分以内が50%,内服後60分以内が89%)。また92%以上が何らかの有効性を自覚していた。効果の持続時間に関しては,回答を得た19例で,4時間が16%,8時間32%,12時間が47%という結果であった。眠気の副作用は33%に認められたが,84%の患者は再処方を希望したことから,本剤の高い有用性が示された。
KOHDA, Futoshi +2 more
openaire +1 more source
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Abstract Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti‐interleukin‐4 receptor (IL‐4R) α in 2017), tralokinumab (anti‐IL‐13 in 2021), lebrikizumab (anti‐IL‐13 in 2023 ...
Svenja Müller +2 more
wiley +1 more source
Development of Analytical Method to Monitor Dissolution of Bepotastine Besilate Tablet
Bepotastine Besilate is an anti-histaminic drug and it is marketed as tablet of strength 10mg. In this study an attempt is made to monitor the dissolution of Bepotastine Besilate tablet. Dissolution study was done for marketed sample using phosphate buffer 6.8, phosphate buffer 4.5 and 0.1 N HCl as dissolution media.
K.K. Pardeshi, M. C. Damle
openaire +1 more source
We evaluated changes in the binding properties of sedative and non-sedative histamine H1–receptor antagonists induced by internalization of H1 receptors in intact human U373 MG astrocytoma cells.
Shigeru Hishinuma +4 more
doaj +1 more source
Orofacial granulomatosis (OFG) is a rare disease entity characterized by nonnecrotizing granulomatous inflammation in the oral and maxillofacial regions, typically characterized by recurrent or persistent edema, primarily in the lips and occasionally in the gingiva. OFG is often associated with Crohn’s disease and sarcoidosis, and an accurate diagnosis
Taku Kimura +7 more
wiley +1 more source
Purpose: The purpose is to study the clinical presentation of seasonal allergic conjunctivitis (SAC) and treatment response to different therapies. Methods: This hospital-based comparative study included all patients aged over 10 years old diagnosed with
Srilekha Berelli +2 more
doaj +1 more source
Background: H1 antihistamines are widely used as therapeutics for allergic diseases. Sedation is a well-known side effect of H1 antihistamines and sometimes it is life-threatening for patients.
Norimasa Izumi +4 more
doaj +1 more source

